ArticleHuman vaccines & immunotherapeutics2018
The gut microbiota and immune checkpoint inhibitors.
Article in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of Concomitant Use of Analgesics on Prognosis in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Gut Microbiota and Extraintestinal Cancers: Mechanistic Insights and Microbiome-Targeted Interventions.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Observational
- Review
- Review
- Gut Microbial Signatures in Sporadic and Hereditary Colorectal Cancer.International journal of molecular sciences · 2021Review
- Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation.Therapeutic advances in medical oncology · 2021Article
- Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors.Therapeutic advances in medical oncology · 2021Article
- The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors.Journal of experimental & clinical cancer research : CR · 2020Review
- Potential benefits of patchouli alcohol in prevention of human diseases: A mechanistic review.International immunopharmacology · 2020Review
- Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer.Carcinogenesis · 2020Article
- Mechanisms of checkpoint inhibition-induced adverse events.Clinical and experimental immunology · 2020Review
- The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors.Biomolecules · 2020Review
- Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth.Cell reports · 2020Article
- Human microbial ecology and the rising new medicine.Annals of translational medicine · 2019Review
- The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies.Clinical and translational medicine · 2019Review
- The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer.Journal of personalized medicine · 2019Review
- Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.Cancer drug resistance (Alhambra, Calif.) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although immunotherapy has been remarkably effective across multiple cancer types, there continues to be a significant number of non-responding patients. A possible factor proposed to influence the efficacy of immunotherapies is the gut microbiome. We discuss the results and implications of recent research on the relationship between the gut microbiome, our immune systems, and immune checkpoint inhibitor therapies including anti-CTLA-4 Ab and anti-PD-1 Ab. While the investigations all exhibit interesting results and conclusions, we find little congruence in the specific bacteria that were found favorable for antitumor responses. It is unclear whether the inconsistencies are due to differential approaches in study design (pre-clinical or clinical subjects, anti-CTLA-4 Ab or anti-PD-1 Ab), experimental methods and measurements (metagenomics sequencing and clustering variations) or subject population dynamics (differential cancer types and baseline characteristics). Moreover, we note studies regarding particular bacterial commensals and autoimmune diseases, which challenge findings from these investigations. We conclude that with the current research, clinical investigators can appreciate the critical role of gut microbiota in mediating immunostimulant response. However, prospective research exploring the biochemical mechanisms which commensal bacteria communicate with each other and the immune system is imperative to understand how they can be adjusted properly for higher immunotherapy response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.